RxDoctor Payments Data

Charles Thiemann, DO

Family Medicine · Cincinnati, OHNPI 1467089029

Payments from drug & device makers

$1,460in general payments, 2019–2025

Across 73 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$309
  • Lilly USA, LLC$261
  • Novo Nordisk$194
  • GSK$151
  • Boehringer Ingelheim$151
  • Pfizer$143
  • plus $250 from 6 others

What the payments were for

  • Food & beverage$1,460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,460 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$53,229
Medicare patients
167
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$30,290
JanuviaSitagliptin Phosphate13$20,658
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,703
FarxigaDapagliflozin Propanediol12$13,086
EliquisApixaban20$12,643
XareltoRivaroxaban23$12,268
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$9,009
Chlorpromazine Hcl17$3,966
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,905
Diclofenac Sodium25$1,205
Celecoxib13$870
Duloxetine Hcl25$842
Albuterol Sulfate HfaAlbuterol Sulfate41$738
Atorvastatin Calcium131$725
Gabapentin57$685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$151$30,29028 claims
MerckJanuvia$48$20,65813 claims
GSKTrelegy Ellipta$151$13,70322 claims
PfizerEliquis$143$12,64320 claims
AbbVieSynthroid$309$50214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →